Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Metastatic Breast Cancer · Recurrent Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Yanxia Shi, Doctor) · shiyx@sysucc.org.cn · 86-020-87343486
Contact: Principal Investigator (Yanxia Shi, Doctor)

Study leads

Yan-xia Shi, Doctor
Principal Investigator
Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Triple Negative Breast Cancer · Locally Advanced Breast Cancer · Recurrent Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Manchester, United Kingdom · Cambridge, United Kingdom

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

PIK3CA Mutation · Solid Tumor, Adult · HER2-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Tucson, United States · San Diego, United States

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Oligometastatic Breast Carcinoma · Breast Cancer · Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States